This page summarizes investment trends and development in neuroinflammation therapeutics for neurodegenerative diseases. Neuroinflammation is increasingly recognized as a key driver of neurodegeneration in Alzheimer's disease, Parkinson's disease, ALS, and other conditions[1].
The field has attracted significant investment from pharmaceutical companies, biotechnology startups, and venture capital over the past decade. This landscape page tracks the key players, funding trends, and development stages of neuroinflammation-targeted therapies[2].
| Metric | Value |
|---|---|
| Total neuroinflammation trials in neurodegeneration | ~300+ |
| Active trials (recruiting/active) | 60+ |
| Mechanisms represented | 12+ |
| Companies with active programs | 40+ |
| Late-stage programs (Phase 3+) | 10+ |
| Mechanism | Description | Trial Count | Development Stage |
|---|---|---|---|
| NLRP3 Inhibitors | Inflammasome blockade | 15+ | Phase 1-2 |
| TREM2 Modulation | Microglial activation modulation | 12+ | Phase 1-2 |
| Anti-IL-1β | Interleukin-1 beta blockade | 20+ | Phase 2-3 |
| Anti-TNFα | Tumor necrosis factor inhibition | 10+ | Phase 2-3 |
| CD33 Targeting | Microglial receptor modulation | 8+ | Phase 1 |
| CSF1R Inhibitors | Microglial depletion | 6+ | Phase 1-2 |
| TYRO2 Inhibitors | Inflammatory signaling blockade | 5+ | Discovery-Phase 1 |
| Minocycline | Broad anti-inflammatory | 25+ | Phase 2-3 |
Neuroinflammation is a hallmark of AD pathophysiology[3]:
PD shows significant neuroinflammatory components[4]:
ALS demonstrates prominent neuroinflammation[5]:
| Company | Approach | Stage | Focus |
|---|---|---|---|
| Roche/Genentech | Anti-TREM2 (semundon) | Phase 2 | Alzheimer's |
| Eli Lilly | NLRP3 inhibitor | Phase 1 | Alzheimer's |
| Novartis | Anti-IL-1β | Phase 2 | Alzheimer's |
| Biogen | Anti-TREM2 | Phase 1 | Alzheimer's |
| AbbVie | CSF1R inhibitor | Phase 1 | ALS, AD |
| Company | Program | Mechanism | Indication |
|---|---|---|---|
| Alector | AL-002 | TREM2 agonist | Alzheimer's |
| Celsius Therapeutics | CEL-383 | TREM2 antagonist | Alzheimer's |
| INmune Bio | XPro1595 | Anti-IL-1β | Alzheimer's, Parkinson's |
| NodThera | NT-0796 | NLRP3 inhibitor | Alzheimer's |
| Orophys | OR-449 | CSF1R inhibitor | ALS |
| Verseon | Novel | NLRP3 inhibitor | Various |
| Year | Investment | Notable Deals |
|---|---|---|
| 2022 | $480M | Phase 2 readouts |
| 2023 | $720M | Big Pharma entry |
| 2024 | $950M | Acquisition activity |
| 2025 (Projected) | $1.3B | Continued growth |
| Trial | Company | Mechanism | Phase | Indication |
|---|---|---|---|---|
| AL-002 | Alector | TREM2 agonist | Phase 2 | Alzheimer's |
| XPro1595 | INmune Bio | Anti-IL-1β | Phase 2 | Alzheimer's |
| Semundon | Roche | Anti-TREM2 | Phase 2 | Alzheimer's |
| NLRP3 Inhibitor | Eli Lilly | NLRP3 | Phase 1 | Alzheimer's |
| Metric | Neuroinflammation | Overall ND |
|---|---|---|
| Total programs | ~300 | ~5,000 |
| Phase 3+ programs | 10 | ~150 |
| Industry-sponsored | 55% | 60% |
| Biomarker inclusion | 35% | 35% |
Key Insight: Neuroinflammation therapeutics represent approximately 6% of the overall neurodegeneration pipeline, with strong Phase 1-2 activity suggesting active development.
Critical needs include:
For current clinical trials targeting neuroinflammatory pathways across neurodegenerative diseases, see:
](https://www.cdc.gov/aging/aging.html)
Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015. ↩︎
Goldman SM. Cytokines in neurodegeneration. Annals of Neurology. 2014. ↩︎
Wang J, et al. Microglia in Alzheimer's disease. Journal of Clinical Investigation. 2015. ↩︎
Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease. Nature Reviews Neuroscience. 2009. ↩︎
Beers DR, et al. Neuroinflammation in ALS. Nature Reviews Neurology. 2008. ↩︎